1. Home
  2. UWMC vs OCGN Comparison

UWMC vs OCGN Comparison

Compare UWMC & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UWM Holdings Corporation

UWMC

UWM Holdings Corporation

N/A

Current Price

$1.25

Market Cap

538.4M

Sector

Finance

ML Signal

N/A

Logo Ocugen Inc.

OCGN

Ocugen Inc.

N/A

Current Price

$0.83

Market Cap

474.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UWMC
OCGN
Founded
1986
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
538.4M
474.8M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
UWMC
OCGN
Price
$1.25
$0.83
Analyst Decision
Hold
Strong Buy
Analyst Count
9
6
Target Price
$1.86
★ $12.17
AVG Volume (30 Days)
★ 12.6M
6.4M
Earning Date
11-04-2026
11-04-2026
Dividend Yield
★ 23.62%
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $3,160,569,000.00
N/A
Revenue This Year
N/A
$35.04
Revenue Next Year
$5.23
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 46.07
N/A
52 Week Low
$0.93
$0.69
52 Week High
$6.15
$2.73

Technical Indicators

Market Signals
Indicator
UWMC
OCGN
Relative Strength Index (RSI) 41.47 45.98
Support Level $0.96 $0.69
Resistance Level $1.55 $1.12
Average True Range (ATR) 0.14 0.09
MACD -0.03 0.02
Stochastic Oscillator 0.74 37.96

Price Performance

Historical Comparison
UWMC
OCGN

About UWMC UWM Holdings Corporation

UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.

About OCGN Ocugen Inc.

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Share on Social Networks: